Waturu Holding A/S
Company announcement nr. 58
Fredericia, February 4th 2021
Lost arbitration incurs additional costs
The company has been involved in an arbitration case concerning an advisory fee, as described in company announcement no. 42, "Addition of note to the interim report 2020".
The case is lost and the amount owed including additional costs of approx. 1,5 MDKK is paid.
About Waturu Holding A/S
Waturu Holding A/S is a Greentech company, which develops innovative water technology for heating or treating water, with the focus on ensuring bacteria-free water and reducing water and energy consumption for heating hot water in properties and thus ensuring CO2 savings. Waturu Holding A/S is a major shareholder in the medical company Watgen Medical A/S and in the technology company Aquaturu A/S.
Further information:
CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
Certified Adviser
Please see company announcement no. 55
Nasdaq First North Growth Market
Important links:
Websites:
www.waturu.com
Financial reports:
www.waturu.com/documents
Further press related news:
www.linkedin.com/company/waturu/
www.facebook.com/WaturuDenmark/
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FLSmidth A/S9.7.2025 08:41:33 CEST | Press release
Correction to Company Announcement no. 15-2025: Transactions under share buy-back programme
Syensqo SA9.7.2025 08:30:00 CEST | Press release
Syensqo - Participation notification by BlackRock Inc.
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom